Oved Amitay is a pharmacologist by training, a drug-developer by trade, and a patient-advocate by choice. He serves as President and Chief Executive Officer at the Solve ME/CFS Initiative- a national organization devoted to making Myalgic Encephalomyelitis (aka, chronic fatigue syndrome) and other infection-associated diseases understood, diagnosed and treated.
Oved and his organization were early to recognize emerging concerns surrounding aftereffects of COVID. In the summer of 2020 Oved co-authored an op-ed calling for an immediate research effort to be initiated, and later co-founded the Long Covid Alliance. Their advocacy led Congress to direct $1.15B to the NIH for funding of Long Covid research. Oved is has dedicated most of his professional career to the development of life-changing therapeutic options for people affected by rare genetic diseases, that resulted in eight Orphan Drugs approved by the FDA. Throughout his career, Oved has had extensive engagements with healthcare systems and patient advocacy organizations around the world. He brings this experience to one of Solve M.E.’s flagship programs- the You+ME Registry and Biobank that forms a virtual research platform.
Before joining Solve M.E., Oved served as Chief Business Officer at CENTOGENE, a global leader in the diagnostics of rare hereditary disorders. He held the position of President and Chief Operating Officer at Arrett Neuroscience. Prior to that, Oved had senior executive positions at Alnylam Pharmaceuticals and Sanofi Genzyme.
